Litcius/Paper detail

Inebilizumab: First Approval

James E. Frampton

2020Drugs110 citationsDOIOpen Access PDF

Topics & Concepts

Neuromyelitis opticaMedicineMyasthenia gravisImmunologyCD19AntibodyAutoantibodyDesensitization (medicine)Monoclonal antibodyRituximabInternal medicineReceptorMultiple Sclerosis Research StudiesImmunotherapy and Immune ResponsesSystemic Sclerosis and Related Diseases
Inebilizumab: First Approval | Litcius